SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...
For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...
The most important benefit of participating in a clinical trial is that patients get early access to potentially new and successful treatments or screenings before the general public. (Karmanos Cancer ...
Real-world studies assess treatment effectiveness and patient experience beyond clinical trial settings, considering broader patient populations. Clinical trials have stricter enrollment criteria, ...
A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NNVC) (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results